Recently,immune checkpoint inhibitors have made great progress in the treatment of malignant tumors,leading to long-term remission in various cancers,including malignant tumors that could not achieve favorable clinical outcomes via traditional therapeutic regimens.However,immunotherapy can induce specific toxic effects known as immune-related adverse events(irAEs).Immune-related pneumonia is an adverse event of immunotherapy that attenuates its clinical effectiveness and endangers the lives of patients.Therefore,it is of great clinical significance to clarify the pathogenesis of immune-related pneumonia and identify relevant biomarkers for its early detection.This article reviews the pathogenesis of immune-induced pneumonia,potential predictive markers,and the new challenges being faced.
NETL
NSTL
万方数据
